Taylor Anthony H, al-Azzawi Farook, Pringle J Howard, Bell Stephen C
Gynaecology Research Group, Department of Obstetrics and Gynaecology, University of Leicester, Leicester Royal Infirmary, Leicester, Leicestershire, LE2 7LX, United Kingdom.
Anticancer Res. 2002 Nov-Dec;22(6C):3993-4003.
The sex hormone 17 beta-estradiol acts as a mitogen in a number of tissues, including the endometrium, through direct interaction with the estrogen receptor (ER alpha). In the protection of the female breast and endometrium from cancer progression it would be advantageous to inhibit estrogenic action, therefore many estrogen receptor antagonists have been made. However, the most clinically relevant anti-estrogens for breast cancer have a detrimental effect on the endometrium and induce or exacerbate existing endometrial oncogenesis. Specific anti-estrogenic potential that is directed against the endometrial ER alpha theoretically could be achieved using antisense oligodeoxyribonucleotide transfection techniques.
To discover the most effective antisense oligodeoxyribonucleotides against the human ER alpha, a series of oligodeoxyribonucleotides were synthesised and tested in a human endometrial cancer cell line that expresses a functional ER alpha.
Transfection with antisense oligodeoxyribonucleotides, directed against different regions of the human ER alpha, significantly inhibited ER alpha protein production without affecting ER beta protein levels. Antisense oligodeoxyribonucleotides directed against the translational start site demonstrated reduced binding of radiolabeled 17 beta-estradiol and a complete inhibition of estrogen-dependent endometrial cancer cell proliferation. The inhibitory effect of the antisense oligodeoxyribonucleotides on ER alpha production and ligand binding was enhanced in the presence of exogenous 17 beta-estradiol.
The data suggest that antisense oligodeoxyribonucleotides against the human ER alpha have the potential of acting as anti-proliferative agents for estrogen-dependent endometrial cancers and may help in elucidating the relative roles of the two estrogen receptors, ER alpha and ER beta, in cell processes other than proliferation.
性激素17β-雌二醇通过与雌激素受体(ERα)直接相互作用,在包括子宫内膜在内的许多组织中充当促有丝分裂原。在保护女性乳腺和子宫内膜免受癌症进展方面,抑制雌激素作用将是有益的,因此已制备了许多雌激素受体拮抗剂。然而,对乳腺癌最具临床相关性的抗雌激素对子宫内膜有不利影响,并诱导或加剧现有的子宫内膜肿瘤发生。理论上,使用反义寡脱氧核糖核苷酸转染技术可以实现针对子宫内膜ERα的特异性抗雌激素潜力。
为了发现针对人ERα最有效的反义寡脱氧核糖核苷酸,合成了一系列寡脱氧核糖核苷酸,并在表达功能性ERα的人子宫内膜癌细胞系中进行了测试。
用针对人ERα不同区域的反义寡脱氧核糖核苷酸转染,可显著抑制ERα蛋白的产生,而不影响ERβ蛋白水平。针对翻译起始位点的反义寡脱氧核糖核苷酸显示放射性标记的17β-雌二醇结合减少,并完全抑制雌激素依赖性子宫内膜癌细胞增殖。在外源17β-雌二醇存在的情况下,反义寡脱氧核糖核苷酸对ERα产生和配体结合的抑制作用增强。
数据表明,针对人ERα的反义寡脱氧核糖核苷酸有潜力作为雌激素依赖性子宫内膜癌的抗增殖剂,并可能有助于阐明两种雌激素受体ERα和ERβ在增殖以外的细胞过程中的相对作用。